Groundbreaking Advances in RET-positive Cancer Research
Innovative research is paving the way for new treatments targeting RET-positive cancers, marking a significant shift in medical approaches. RETpositive, a dedicated advocacy group, is working tirelessly to support research and increase awareness of these unique cancers.
The Challenge of RET-Positive Cancers
RET gene alterations are linked to a variety of cancers, including non-small cell lung cancer, thyroid cancer, and even some colon and breast cancers. It is estimated that 1-2% of non-small cell lung cancer cases have RET rearrangements. While there are now two RET tyrosine kinase inhibitors available, resistance from tumors often develops, highlighting the urgent need for new therapeutic strategies.
Importance of the RETpositive/LUNGevity Translational Research Award
The RETpositive/LUNGevity Translational Research Award aims to promote groundbreaking studies that could transform the outcomes for patients diagnosed with RET-positive cancers. RETpositive, through this initiative, is keen to foster high-impact research that can truly assist individuals battling these cancers.
Meet the Award Recipient
We are thrilled to announce that Dr. Justin Drake, PhD, from the University of Minnesota, has been chosen as the recipient of the prestigious RETpositive/LUNGevity Translational Research Award. His project, titled “Novel Protein Degraders for Treating RET-Positive Cancers,” aims to implement an innovative technology known as PROTACs.
What are PROTACs?
PROTACs, or PROteolysis Targeting Chimeras, represent a breakthrough in treatment options. This technology offers a novel way to tag and degrade specific proteins, such as RET, which promotes tumor growth. By utilizing the body’s natural degradation mechanisms, Dr. Drake and his team hope to tackle the persistent issue of drug resistance, thereby opening new avenues for effective cancer treatment.
The Importance of Collaboration
Dr. Upal Basu Roy, the executive director of LUNGevity Research, expressed enthusiasm about this partnership: "Through our collaboration with RETpositive, we are tackling drug resistance and laying the groundwork for innovative approaches to treat RET-positive cancers." This collaboration signifies a pivotal moment in research, potentially benefiting patients far beyond the RET-positive cancer community.
About RETpositive
RETpositive is a non-profit organization dedicated to improving the lives of those affected by RET-driven cancers. By boosting awareness, community support, and funding for medical research, they aim to enhance the quality of life and extend life expectancy for these patients.
About LUNGevity Foundation
LUNGevity Foundation is a preeminent organization focused on lung cancer, striving to change the landscape of lung cancer diagnosis and treatment. Their mission emphasizes improving quality of life and promoting health equity throughout the healthcare system.
The Vision of LUNGevity
LUNGevity employs innovative research methods to detect lung cancer early, develop new treatments, and foster a diverse generation of lung cancer investigators. Their advocacy efforts strive to ensure that every individual has equitable access to comprehensive screenings, treatments, and breakthrough therapies.
Statistics on Lung Cancer in the US
Understanding the gravity of lung cancer is crucial. Approximately 1 in 18 Americans will receive a lung cancer diagnosis during their lives, with more than 234,000 new cases identified each year. Notably, a significant portion of new diagnoses occurs in individuals without a history of tobacco use. Despite advancements, lung cancer remains one of the deadliest forms of cancer globally.
Frequently Asked Questions
What is the focus of the RETpositive/LUNGevity Translational Research Award?
The award supports innovative research targeting RET-positive cancers, aiming to enhance treatment options for patients.
Who is Dr. Justin Drake?
Dr. Justin Drake is a prominent researcher from the University of Minnesota, recognized for his work on novel protein degrader technologies aimed at treating RET-positive cancers.
What are PROTACs?
PROTACs are innovative compounds that target specific proteins for degradation, offering a potential new method to overcome treatment resistance in cancer patients.
How does RETpositive support cancer patients?
RETpositive provides advocacy, community support, and funding for research efforts aimed at improving the lives and treatment outcomes of RET-positive cancer patients.
What impact does LUNGevity Foundation have?
LUNGevity Foundation leads initiatives to advance research, advocate for equitable healthcare access, and support lung cancer patients in their journey.
